- Home
- LEGT vs ABEO Comparison
LEGT vs ABEO Comparison
Compare LEGT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.36
Company Overview
Basic Information| Metric | LEGT | ABEO |
|---|---|---|
| Founded | 2023 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.6M | 281.0M |
| IPO Year | 2024 | 1980 |
Fundamental Metrics
Financial Performance| Metric | LEGT | ABEO |
|---|---|---|
| Price | $10.86 | $5.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 47.1K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.33 | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,590.36 |
| P/E Ratio | $32.91 | ★ $4.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.29 | $3.93 |
| 52 Week High | $11.25 | $7.54 |
Technical Indicators
Market Signals| Indicator | LEGT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 59.34 |
| Support Level | $10.77 | $4.53 |
| Resistance Level | $10.86 | $5.61 |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 36.36 | 78.90 |
Price Performance
Historical Comparison LEGT
ABEO
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.